SLC1A5 and breast carcinoma: This regulates the stability of SLC1A5 protein, thereby reducing the uptake of glutamine by cells, inhibiting the mechanistic target of rapamycin (mTOR)-signaling pathway and reducing the growth rate of breast cancer cells.